pirenzepine has been researched along with Agranulocytosis in 23 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
Agranulocytosis: A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The authors report a case of agranulocytosis induced by olanzapine and reviewed the 11 cases reported in the literature." | 6.41 | Olanzapine-induced agranulocytosis: a case report and review of the literature. ( Mari-Alfonso, B; Naval-Sendra, E; Ruiz-Ripoll, A; Tolosa-Vilella, C, 2002) |
| "We report a case of agranulocytosis induced by olanzapine." | 5.30 | Olanzapine-induced agranulocytosis. ( Felber, W; Heilemann, H; Naumann, R; Reuster, T, 1999) |
| " The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only)." | 4.80 | Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations. ( , 1998) |
| "How to best treat psychotic patients who have had past clozapine-induced agranulocytosis or granulocytopenia remains a problem." | 3.70 | Olanzapine treatment after clozapine-induced granulocytopenia in 3 patients. ( Ananth, J; Arai, Y; Burgoyne, KS; Gadasally, R; Smith, MW; Swartz, JR, 1999) |
| "Clozapine is associated with a high incidence of agranulocytosis." | 3.69 | Structural features associated with reactive metabolite formation in clozapine analogues. ( Fu, JM; Rakhit, S; Tehim, A; Uetrecht, J; Zahid, N, 1997) |
| " Surprisingly, there has been little relationship between the pivotal trials designed for FDA approval and current dosing strategies in broader clinical settings." | 2.41 | New antipsychotic medications: more than old wine and new bottles. ( Schulz, SC, 2000) |
| "The authors report a case of agranulocytosis induced by olanzapine and reviewed the 11 cases reported in the literature." | 2.41 | Olanzapine-induced agranulocytosis: a case report and review of the literature. ( Mari-Alfonso, B; Naval-Sendra, E; Ruiz-Ripoll, A; Tolosa-Vilella, C, 2002) |
| " Neutrophils from two patients with a history of clozapine-induced agranulocytosis seemed to be more sensitive to the toxic effects of the clozapine reactive metabolite; however, the numbers are too small to draw any definite conclusions." | 1.30 | A comparison of the oxidation of clozapine and olanzapine to reactive metabolites and the toxicity of these metabolites to human leukocytes. ( Gardner, I; MacCrimmon, D; Uetrecht, JP; Zahid, N, 1998) |
| "We report a case of agranulocytosis induced by olanzapine." | 1.30 | Olanzapine-induced agranulocytosis. ( Felber, W; Heilemann, H; Naumann, R; Reuster, T, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.35) | 18.7374 |
| 1990's | 12 (52.17) | 18.2507 |
| 2000's | 10 (43.48) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Iverson, S | 1 |
| Zahid, N | 3 |
| Uetrecht, JP | 2 |
| Uetrecht, J | 1 |
| Tehim, A | 1 |
| Fu, JM | 1 |
| Rakhit, S | 1 |
| Flynn, SW | 1 |
| Altman, S | 1 |
| MacEwan, GW | 1 |
| Black, LL | 1 |
| Greenidge, LL | 1 |
| Honer, WG | 1 |
| Gardner, I | 1 |
| MacCrimmon, D | 1 |
| Chatterton, R | 1 |
| Finkel, B | 1 |
| Lerner, A | 1 |
| Oyffe, I | 1 |
| Rudinski, D | 1 |
| Sigal, M | 1 |
| Weizman, A | 1 |
| Lambert, T | 1 |
| Swartz, JR | 1 |
| Ananth, J | 1 |
| Smith, MW | 1 |
| Burgoyne, KS | 1 |
| Gadasally, R | 1 |
| Arai, Y | 1 |
| Beasley, CM | 1 |
| Dettling, M | 1 |
| Cascorbi, I | 1 |
| Hellweg, R | 1 |
| Deicke, U | 1 |
| Weise, L | 1 |
| Müller-Oerlinghausen, B | 1 |
| Naumann, R | 2 |
| Felber, W | 2 |
| Heilemann, H | 2 |
| Reuster, T | 2 |
| Schulz, SC | 1 |
| Oyewumi, LK | 1 |
| Al-Semaan, Y | 1 |
| Schuld, A | 1 |
| Kraus, T | 1 |
| Hinze-Selch, D | 1 |
| Haack, M | 1 |
| Pollmächer, T | 1 |
| Schuler, U | 1 |
| Fülle, M | 1 |
| Garcia, K | 1 |
| Heeringa, M | 1 |
| van Grootheest, AC | 1 |
| Konakanchi, R | 1 |
| Grace, JJ | 1 |
| Szarowicz, R | 1 |
| Pato, MT | 1 |
| Hong, X | 1 |
| Wang, X | 1 |
| Tolosa-Vilella, C | 1 |
| Ruiz-Ripoll, A | 1 |
| Mari-Alfonso, B | 1 |
| Naval-Sendra, E | 1 |
| Stricker, BH | 1 |
| Meyboom, RH | 1 |
| Bleeker, PA | 1 |
| van Wieringen, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Quetiapine in the Treatment of Psychotic Depression - a Pilot Study[NCT00751504] | Phase 3 | 16 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for pirenzepine and Agranulocytosis
| Article | Year |
|---|---|
Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Agranulocytosis; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Central Nervous Syst | 1998 |
New antipsychotic medications: more than old wine and new bottles.
Topics: Agranulocytosis; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzot | 2000 |
Olanzapine-induced agranulocytosis: a case report and review of the literature.
Topics: Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Humans; Male; Middle Aged; Olanzapine; Piren | 2002 |
20 other studies available for pirenzepine and Agranulocytosis
| Article | Year |
|---|---|
Predicting drug-induced agranulocytosis: characterizing neutrophil-generated metabolites of a model compound, DMP 406, and assessing the relevance of an in vitro apoptosis assay for identifying drugs that may cause agranulocytosis.
Topics: Agranulocytosis; Antipsychotic Agents; Apoptosis; Benzodiazepines; Chromatography, High Pressure Liq | 2002 |
Structural features associated with reactive metabolite formation in clozapine analogues.
Topics: Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Binding Sites; Chromatography, High Pressure | 1997 |
Prolongation of clozapine-induced granulocytopenia associated with olanzapine.
Topics: Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Clozapine; Drug Interactions; Humans; Olanza | 1997 |
A comparison of the oxidation of clozapine and olanzapine to reactive metabolites and the toxicity of these metabolites to human leukocytes.
Topics: Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Clozapine; HL-60 Cells; Humans; Hypochlorous | 1998 |
Experiences with clozapine and olanzapine.
Topics: Adult; Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Clozapine; Female; Humans; Male; Midd | 1998 |
Olanzapine: hematological reactions.
Topics: Adult; Aged; Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Olanzapin | 1998 |
Olanzapine treatment in patients with typical and atypical neuroleptic-associated agranulocytosis.
Topics: Adult; Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Clopenthixol; Dose-Response Relations | 1998 |
Olanzapine after clozapine: the rare case of prolongation of granulocytopaenia.
Topics: Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Clozapine; Drug Administration Schedule; Hum | 1998 |
Olanzapine treatment after clozapine-induced granulocytopenia in 3 patients.
Topics: Adult; Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Clozapine; Follow-Up Studies; Humans; | 1999 |
Response to letter of Professor Tim Lambert.
Topics: Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Clozapine; Drug Interactions; Humans; Olanza | 1999 |
Genetic determinants of drug-induced agranulocytosis: potential risk of olanzapine?
Topics: Adult; Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Female; Genetic Predisposition to Dis | 1999 |
Olanzapine-induced agranulocytosis.
Topics: Adult; Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Humans; Male; Olanzapine; Pirenzepine | 1999 |
Olanzapine: safe during clozapine-induced agranulocytosis.
Topics: Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Male; Middle Aged; Olanza | 2000 |
Side Effects of Antipsychotic Medications: Physician's Choice of Medication and Patient Compliance. Dallas, Texas, California. January 22, 1999. Proceedings of a roundtable.
Topics: Agranulocytosis; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Dibenzoth | 2000 |
Granulocyte colony-stimulating factor plasma levels during clozapine- and olanzapine-induced granulocytopenia.
Topics: Adult; Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Clozapine; Cytokines; Female; Granulo | 2000 |
Are there genetic determinants of olanzapine-induced agranulocytosis?
Topics: Agranulocytosis; Antipsychotic Agents; Benzodiazepines; HLA-A2 Antigen; Humans; Olanzapine; Pirenzep | 2000 |
[Atypical antipsychotics].
Topics: Adverse Drug Reaction Reporting Systems; Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Clo | 2000 |
Olanzapine prolongation of granulocytopenia after clozapine discontinuation.
Topics: Adult; Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Clozapine; Female; Humans; Olanzapine | 2000 |
Agranulocytosis and neutropenia with typical and atypical neuroleptics.
Topics: Adult; Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Clozapine; Female; Humans; Leukocyte | 2001 |
Blood disorders associated with pirenzepine.
Topics: Aged; Aged, 80 and over; Agranulocytosis; Female; Humans; Male; Pirenzepine; Thrombocytopenia | 1986 |